BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25542698)

  • 1. Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications.
    Robaina MC; Faccion RS; Arruda VO; de Rezende LM; Vasconcelos GM; Apa AG; Bacchi CE; Klumb CE
    Leuk Res; 2015 Feb; 39(2):248-56. PubMed ID: 25542698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma.
    Klangby U; Okan I; Magnusson KP; Wendland M; Lind P; Wiman KG
    Blood; 1998 Mar; 91(5):1680-7. PubMed ID: 9473234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland.
    Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A
    J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
    Robaina MC; Mazzoccoli L; Arruda VO; Reis FR; Apa AG; de Rezende LM; Klumb CE
    Exp Mol Pathol; 2015 Apr; 98(2):200-7. PubMed ID: 25746661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promoter hypermethylation: a common cause of reduced p16(INK4a) expression in uveal melanoma.
    van der Velden PA; Metzelaar-Blok JA; Bergman W; Monique H; Hurks H; Frants RR; Gruis NA; Jager MJ
    Cancer Res; 2001 Jul; 61(13):5303-6. PubMed ID: 11431374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer.
    Kurakawa E; Shimamoto T; Utsumi K; Hirano T; Kato H; Ohyashiki K
    Int J Oncol; 2001 Aug; 19(2):277-81. PubMed ID: 11445839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Several mechanisms lead to the inactivation of the CDKN2A (P16), P14ARF, or CDKN2B (P15) genes in the GCB and ABC molecular DLBCL subtypes.
    Guney S; Jardin F; Bertrand P; Mareschal S; Parmentier F; Picquenot JM; Tilly H; Bastard C
    Genes Chromosomes Cancer; 2012 Sep; 51(9):858-67. PubMed ID: 22619049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis.
    Tang S; Luo H; Yu J; Yang D; Shu J
    Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular analysis of the Ink4a/Rb1-Arf/Tp53 pathways in radon-induced rat lung tumors.
    Bastide K; Guilly MN; Bernaudin JF; Joubert C; Lectard B; Levalois C; Malfoy B; Chevillard S
    Lung Cancer; 2009 Mar; 63(3):348-53. PubMed ID: 18656278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.
    Wilda M; Bruch J; Harder L; Rawer D; Reiter A; Borkhardt A; Woessmann W
    Leukemia; 2004 Mar; 18(3):584-8. PubMed ID: 14712292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. INK4a-ARF alterations and p53 mutations in primary and consecutive squamous cell carcinoma of the head and neck.
    Weber A; Bellmann U; Bootz F; Wittekind C; Tannapfel A
    Virchows Arch; 2002 Aug; 441(2):133-42. PubMed ID: 12189502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ubiquitin-mediated protein degradation and methylation-induced gene silencing cooperate in the inactivation of the INK4/ARF locus in Burkitt lymphoma cell lines.
    Roberti A; Rizzolio F; Lucchetti C; de Leval L; Giordano A
    Cell Cycle; 2011 Jan; 10(1):127-34. PubMed ID: 21200153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The RB (pRb2/p16) and p53 (p14/p53/p21) tumor-suppressor pathways in endemic Burkitt lymphoma.
    Kalungi S; Wabinga H; Bostad L
    J Pediatr Hematol Oncol; 2011 Mar; 33(2):e54-9. PubMed ID: 21127431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigallocatechin-3-gallate and trichostatin A synergistically inhibit human lymphoma cell proliferation through epigenetic modification of p16INK4a.
    Wu DS; Shen JZ; Yu AF; Fu HY; Zhou HR; Shen SF
    Oncol Rep; 2013 Dec; 30(6):2969-75. PubMed ID: 24064951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative evaluation of p16(INK4a) promoter methylation using pyrosequencing in de novo diffuse large B-cell lymphoma.
    Zainuddin N; Kanduri M; Berglund M; Lindell M; Amini RM; Roos G; Sundström C; Enblad G; Rosenquist R
    Leuk Res; 2011 Apr; 35(4):438-43. PubMed ID: 21035853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CDKN2A promoter hypermethylation in astrocytomas is associated with age and sex.
    Alves MK; Faria MH; Neves Filho EH; Ferrasi AC; Pardini MI; de Moraes Filho MO; Rabenhorst SH
    Int J Surg; 2013; 11(7):549-53. PubMed ID: 23721661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
    Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
    Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Promoter hypermethylation and quantitative expression analysis of CDKN2A (p14ARF and p16INK4a) gene in esophageal squamous cell carcinoma.
    Ito S; Ohga T; Saeki H; Watanabe M; Kakeji Y; Morita M; Yamada T; Maehara Y
    Anticancer Res; 2007; 27(5A):3345-53. PubMed ID: 17970080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.